A comparison of the effect of doxorubicin and phenol on the skeletal muscle. May doxorubicin be a new alternative treatment agent for spasticity?

Journal of Pediatric Orthopaedics Part B

Volumn 14, Issue 2, 2005, Pages 134-138

  Cullu, Emre ^a,b   Ozkan, Ilhan ^a   Culhaci, Nil ^a   Alparslan, Bulent ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Chemomyectomy; Doxorubicin; Drug effects; Metabolism; Muscle; Muscle denervation; Pharmacology; Phenol; Physiology; Therapeutic use

Indexed keywords

DOXORUBICIN; PHENOL;

ANIMAL TISSUE; ARTICLE; CELL VACUOLE; DEGENERATION; DOSE RESPONSE; DRUG EFFECT; FIBROSIS; HISTOPATHOLOGY; INFLAMMATION; INJECTION; KRUSKAL WALLIS TEST; MUSCLE ATROPHY; NECROSIS; NEUROMUSCULAR DISEASE; NONHUMAN; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; RANK SUM TEST; RAT; SKELETAL MUSCLE; SPASTICITY;

EID: 14744272966     PISSN: 1060152X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01202412-200503000-00015     Document Type: Article

References (26)

1. Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve 1997; 6:S1-S13.
2. Gormley ME Jr, O'Brien CF, Yablon SA. A clinical overview of treatment decisions in the management of spasticity. Muscle Nerve 1997; 6:S14-S20.
3. Koman LA, Mooney JF 3rd, Smith BP. Neuromuscular blockade in the management of cerebral palsy. J Child Neurol 1996; 11(suppl 1):S23-S28.
4. Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK. Botulinum toxin A compared with streching cast in the treatment of spastic equinus: A randomised prospective trial. J Pediatr Orthop 1998; 18:304-311.
5. Koman LA, Smith BP, Tingey CT, Mooney JF, Slone S, Naughton MJ. The effect of botulinum toxin type A injections on the natural history of equinus foot deformity in paediatric cerebral palsy patients. Eur J Neurol 1999; 6(suppl 4):S19-S22.
6. Aoki KG. Preclinical update on BOTOX (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations. Eur J Neurol; 1999; 6(suppl 4):S3-S10.
7. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 1997; 6:S146-S168.
8. Bodine-Fowler SC, Allsing S, Botte MJ. Time course of muscle atrophy and recovery following a phenol-induced nerve block. Muscle Nerve 1996; 19:497-504.
9. Easton JK, Ozel T, Halpern D. Intramuscular neurolysis for spasticity in children. Arch Phys Med Rehab 1979; 60:155-158.
10. Greenbaum MG, Young MA, Frank JM. Attenuation of facial muscle spasticity with intramuscular phenol neurolysis. Arch Phys Med Rehab 1993; 74:217-219.
11. Griffith ER, Melamphy CN. General anesthesia use in phenol intramuscular neurolysis in young children with spasticity. Arch Phys Med Rehab 1977; 58:154-157.
12. Halpern D. Histologic studies in animals after intramuscular neurolysis with phenol. Arch Phys Med Rehabil 1977; 58:438-443.
13. Zorzato F, Salviati G, Facchinetti T, Volpe P. Doxorubicin induces calcium release from terminal cisternae of skeletal muscle. J Biol Chem 1985; 260:7349-7355.
14. Falkenberg JH, Iaizzo PA, McLoon LK. Physiological assessment of muscle strength in vitro after direct injection of doxorubicin into rabbit sternocleidomastoid muscle. Mov Disord 2001; 16:683-692.
15. Falkenberg JH, Iaizzo PA, McLoon LK. Muscle strength following direct injection of doxorubicin into rabbit sternocleidomastoid muscle in situ. Muscle Nerve 2002; 25:735-741.
16. Goding GS Jr, Pernell KJ. Doxorubicin chemomyectomy: effects on evoked vocal fold tension and mucosal wave. Ann Otol Rhinol Laryngol 2000; 109:294-300.
17. McLoon LK, Bauer G, Wirtschafter J. Quantification of muscle loss in the doxorubicin- treated orbicularis oculi of the monkey. Invest Ophthal Vis Sci 1991; 32:1667-1673.
18. McLoon LK, Wirtschafter J. Doxorubicin chemomyectomy: Injection of monkey orbicularis oculi results in selective muscle injury. Invest Ophthal Vis Sci 1988; 29:1854-1859.
19. McLoon LK, Wirtschafter J, Cameron JD. Muscle loss from doxorubicin injections into the eyelids of a patient with blepharospasm. Am J Ophthal 1993; 116:646-648.
20. McLoon LK, Kirsch JD, Cameron S, Wirtschafter J. Injection of doxorubicin into rabbit eyelid does not result in loss of facial motor neurons. Brain Res 1994; 641:105-110.
21. McLoon LK, Lou XX, Wirtschafter J. Acute morphologic changes in orbicularis oculi muscle after doxorubicin injection into the eyelid. Muscle Nerve 1993; 16:737-743.
22. Wirtschafter J. Clinical doxorubicin chemomyectomy. An experimental treatment for benign essential blepharospasm and hemifascial spasm. Ophthalmology 1991; 98:357-366.
23. Wirtschafter J, McLoon LK. Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm. Ophthalmology 1998; 105:342-346.
24. Cullu E, Ozkan I, Culhaci N, Alparslan B, Dikicioglu E, Savk SO. The effects of doxorubicin on skeletal muscle [in Turkish]. Acta Orthop Traumatol Turc 2000; 34:84-88.
25. Cullu E, Ozkan I, Culhaci N, Alparslan B, Dikicioglu E, Savk SO. Chemomyectomy effects of doxorubicin: An experimental study [in Turkish]. Acta Orthop Traumatol Turc 2003; 37:323-329.
26. Nathan PW, Sears TA, Smith MC. Effects of phenol solutions on the nerve roots of the cat: an electrophysiological and histological study. J Neurol Sci 1965; 2:7-29.